BR112014013544A2 - materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata - Google Patents

materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata

Info

Publication number
BR112014013544A2
BR112014013544A2 BR112014013544A BR112014013544A BR112014013544A2 BR 112014013544 A2 BR112014013544 A2 BR 112014013544A2 BR 112014013544 A BR112014013544 A BR 112014013544A BR 112014013544 A BR112014013544 A BR 112014013544A BR 112014013544 A2 BR112014013544 A2 BR 112014013544A2
Authority
BR
Brazil
Prior art keywords
prostate cancer
prognosis
diagnosis
evaluation
materials
Prior art date
Application number
BR112014013544A
Other languages
English (en)
Other versions
BR112014013544A8 (pt
Inventor
Pestova Ekaterina
Sokolova Irina
Morrison Larry
Zhang Ying
Original Assignee
Abbott Molecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Molecular Inc filed Critical Abbott Molecular Inc
Priority to BR122015032159A priority Critical patent/BR122015032159A2/pt
Publication of BR112014013544A2 publication Critical patent/BR112014013544A2/pt
Publication of BR112014013544A8 publication Critical patent/BR112014013544A8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
    • G01N33/48721—Investigating individual macromolecules, e.g. by translocation through nanopores
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

resumo "materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata" um método para detectar o câncer da próstata que compreende contatar uma amostra de células da próstata do paciente com um conjunto de sondas marca-das de modo detectável, sob condições de hibridização, e determinar a presença de anormalidades cromossômicas no tecido de tumor, pin (neoplasia intraepitelial), tecido histologicamente benigno e hiperplasia prostática benigna (bph); um método para combinar imunofluorescência e fish (if-fish) para facilitar a avaliação de anormalidades cromossômicas; um conjunto de sondas; e um kit compreendendo o conjunto de sondas e instruções para diagnosticar o câncer da próstata em um paci-ente.
BR112014013544A 2011-12-30 2012-12-20 materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata BR112014013544A8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122015032159A BR122015032159A2 (pt) 2011-12-30 2012-12-20 método para detectar câncer de próstata utilizando conjunto de sondas compreendendo sondas lócus específicas para myc e para homólogo de fosfatase e tensina (pten) e sondas centroméricas para cromossomos 7, 8 e 10, bem como conjunto de sondas e kit

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161582212P 2011-12-30 2011-12-30
PCT/US2012/070746 WO2013101612A1 (en) 2011-12-30 2012-12-20 Materials and methods for diagnosis, prognosis and assessment of therapeutic/prophylactic treatment of prostate cancer

Publications (2)

Publication Number Publication Date
BR112014013544A2 true BR112014013544A2 (pt) 2017-06-13
BR112014013544A8 BR112014013544A8 (pt) 2017-06-13

Family

ID=47559690

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122015032159A BR122015032159A2 (pt) 2011-12-30 2012-12-20 método para detectar câncer de próstata utilizando conjunto de sondas compreendendo sondas lócus específicas para myc e para homólogo de fosfatase e tensina (pten) e sondas centroméricas para cromossomos 7, 8 e 10, bem como conjunto de sondas e kit
BR112014013544A BR112014013544A8 (pt) 2011-12-30 2012-12-20 materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122015032159A BR122015032159A2 (pt) 2011-12-30 2012-12-20 método para detectar câncer de próstata utilizando conjunto de sondas compreendendo sondas lócus específicas para myc e para homólogo de fosfatase e tensina (pten) e sondas centroméricas para cromossomos 7, 8 e 10, bem como conjunto de sondas e kit

Country Status (7)

Country Link
US (2) US9617601B2 (pt)
EP (1) EP2798082B1 (pt)
JP (2) JP6203752B2 (pt)
CN (2) CN110055325A (pt)
BR (2) BR122015032159A2 (pt)
ES (1) ES2633183T3 (pt)
WO (1) WO2013101612A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633183T3 (es) 2011-12-30 2017-09-19 Abbott Molecular Inc. Materiales y procedimientos para el diagnóstico, pronóstico y evaluación del tratamiento terapéutico/profiláctico del cáncer de próstata
US9994912B2 (en) * 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
EP3286565A1 (en) * 2015-04-21 2018-02-28 Genentech, Inc. Compositions and methods for prostate cancer analysis
JP7082489B2 (ja) * 2016-02-09 2022-06-08 公益財団法人がん研究会 希少造血器腫瘍の診断マーカー、検査方法、治療薬及びスクリーニング方法
CN109593835B (zh) * 2017-09-29 2023-12-12 深圳华大基因股份有限公司 用于微量ffpe rna样本评估的方法、试剂盒及应用
US11253522B2 (en) * 2018-04-28 2022-02-22 The Regents Of The University Of California Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
CN110596060B (zh) * 2019-09-12 2020-08-21 江南大学 一种检测前列腺特异性抗原的光谱分析中荧光传感器的构建方法及其应用
CN111471678A (zh) * 2020-04-29 2020-07-31 河南赛诺特生物技术有限公司 一种人8号染色体着丝粒探针及其制备方法、试剂盒
GB2596271A (en) * 2020-05-06 2021-12-29 Nottingham Univ Hospitals Nhs Trust Cancer screening test
CN111863245A (zh) * 2020-07-30 2020-10-30 上海妙一生物科技有限公司 目标对象评估系统、方法、设备和存储介质
CN113025721A (zh) * 2021-04-28 2021-06-25 苏州宏元生物科技有限公司 一种前列腺癌诊断和预后评估试剂盒
CN113567672A (zh) * 2021-07-26 2021-10-29 江南大学附属医院 一种检测腹水或腹腔灌洗液中癌细胞的试剂盒
CN117448456B (zh) * 2023-12-26 2024-04-19 广州安必平医药科技股份有限公司 用于鉴别涎腺肿瘤良恶性的分子靶标、探针组合、试剂盒及其应用
CN118067487A (zh) * 2024-04-24 2024-05-24 中日友好医院(中日友好临床医学研究所) 一种基于酪胺信号放大技术的足细胞免疫荧光染色方法及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
DE69330750T2 (de) 1992-03-04 2002-07-04 The Regents Of The University Of California, Oakland Vergleichende genomhybridisierung
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5658730A (en) 1994-12-23 1997-08-19 Ctrc Research Foundation Methods of human prostate cancer diagnosis
US5925519A (en) 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
US6262242B1 (en) 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6613510B2 (en) 1999-04-28 2003-09-02 Mayo Foundation For Medical Education And Research Methods and probe sets for determining prostate cancer prognosis
WO2002066685A1 (en) * 2001-02-20 2002-08-29 Vysis, Inc. Methods and probes for the detection of cancer
WO2002100246A2 (en) 2001-06-12 2002-12-19 Board Of Regents, The University Of Texas System Methods of detecting, diagnosing and treating cancer and identifying neoplastic progression
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7604965B2 (en) 2003-04-03 2009-10-20 Fluidigm Corporation Thermal reaction device and method for using the same
CA2550429A1 (en) 2004-02-06 2005-08-25 Health Research, Inc. Method of prognosis of metastasis by detection of fra12e fragile site within the smrt gene/locus at chromosome 12q24
AU2006232378A1 (en) 2005-04-01 2006-10-12 Amgen Inc. Epidermal growth factor receptor gene copy number
ES2644045T3 (es) * 2005-09-02 2017-11-27 The Regents Of The University Of California Métodos y combinaciones de sondas para detectar melanoma
JP5512125B2 (ja) 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
EP2155897A2 (en) 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
AU2008295992B2 (en) 2007-09-07 2014-04-17 Fluidigm Corporation Copy number variation determination, methods and systems
EP2205763A2 (en) * 2007-09-14 2010-07-14 Ventana Medical Systems, Inc. Prostate cancer biomarkers
GB0809689D0 (en) 2008-05-28 2008-07-02 Cancer Res Inst Royal Markers for prostate cancee
US20110230361A1 (en) 2008-11-14 2011-09-22 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
WO2010099577A1 (en) 2009-03-04 2010-09-10 The University Of Queensland Cancer biomarkers and uses therefor
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US8179305B2 (en) 2009-08-12 2012-05-15 Tektronix, Inc. Enhanced impulse response measurement of an FM radar transmitter pulse
EP2539355B1 (en) * 2010-02-26 2016-10-05 Ventana Medical Systems, Inc. In-situ hybridization with polytag probes
CA2696545C (en) * 2010-03-15 2019-08-06 Queen's University At Kingston Methods, probe sets, and kits for detection of deletion of tumor suppressor genes by fluorescence in situ hybridization
ES2633183T3 (es) 2011-12-30 2017-09-19 Abbott Molecular Inc. Materiales y procedimientos para el diagnóstico, pronóstico y evaluación del tratamiento terapéutico/profiláctico del cáncer de próstata

Also Published As

Publication number Publication date
US10302645B2 (en) 2019-05-28
WO2013101612A1 (en) 2013-07-04
US20170184599A1 (en) 2017-06-29
EP2798082A1 (en) 2014-11-05
CN110055325A (zh) 2019-07-26
JP6203752B2 (ja) 2017-09-27
US9617601B2 (en) 2017-04-11
BR112014013544A8 (pt) 2017-06-13
US20130171638A1 (en) 2013-07-04
JP2018007679A (ja) 2018-01-18
JP2015503348A (ja) 2015-02-02
CN104011227A (zh) 2014-08-27
ES2633183T3 (es) 2017-09-19
BR122015032159A2 (pt) 2019-08-27
EP2798082B1 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
BR112014013544A2 (pt) materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata
Darin et al. Role of indocyanine green in sentinel node mapping in gynecologic cancer: is fluorescence imaging the new standard?
Kumar et al. How should we manage oral leukoplakia?
Mora et al. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance
Barwari et al. Differentiation between normal renal tissue and renal tumours using functional optical coherence tomography: a phase I in vivo human study
Lerner et al. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder
Ahmad et al. Oral 5‐aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma–a prospective audit
Kaltoft et al. Primary localised cutaneous amyloidosis–systematic review
BR112015023783A2 (pt) método para diagnóstico e tratamento de metastase no câncer
Li et al. Prognostic value of responsiveness of neoadjuvant chemotherapy before surgery for patients with stage IB2/IIA2 cervical cancer
WO2012008807A3 (ko) ＴＧａｓｅ２ 및 ＶＨＬ의 신장암 진단 마커로서의 용도
Kołodziej et al. Review of current optical diagnostic techniques for non-muscle-invasive bladder cancer
Marzouki et al. Use of fluorescent light in detecting malignant and premalignant lesions in the oral cavity: a prospective, single-blind study.
Webber et al. Effectiveness and limitations of reflectance confocal microscopy in detecting persistence of basal cell carcinomas: a preliminary study
CN105154448A (zh) Rp11-1023l17.1作为前列腺癌分子靶标及其在诊断试剂盒中的应用
Xu et al. Bichromatic imaging with hemicyanine fluorophores enables simultaneous visualization of non-alcoholic fatty liver disease and metastatic intestinal cancer
CN105154447A (zh) Ac016745.3作为前列腺癌分子靶标及其在诊断试剂盒中的应用
Colcord et al. Preoperative muscle strength is a predictor of outcomes after esophagectomy
Xu et al. Protein@ cyanine‐based NIR‐II lymphography enables the supersensitive visualization of lymphedema and tumor lymphatic metastasis
Salomon et al. The feasibility of prostate cancer detection by triple spectroscopy
Lay et al. Detecting positive surgical margins: utilisation of light‐reflectance spectroscopy on ex vivo prostate specimens
Tombal Over-and underdiagnosis of prostate cancer: the dangers
EP1988164A4 (en) METHOD FOR TESTING THE SENSITIVITY OF SOLIC CANCER AGAINST A TYROSINE KINASE INHIBITOR AND CORRESPONDING TEST REQUIREMENTS
Penna et al. Improving lymph node yield in retroperitoneal lymph node dissection using fluorescent molecular imaging: a novel method of localizing lymph nodes in Guinea pig model
Hale et al. Advances in cystoscopic surveillance of superficial bladder cancer: detection of the invisible tumor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]